Oligonucleotide therapeutics have emerged as a third distinct platform for drug discovery within the pharmaceutical industry. Five oligonucleotide-based drugs have been approved by the US FDA and over 100 oligonucleotides drugs are currently at different stages of human trials. Several of these oligonucleotide drugs are modified using the phosphorothioate (PS) backbone modification where one of the nonbridging oxygen atoms of the phosphodiester linkage is replaced with sulfur. In this review, we summarize our knowledge on receptor-mediated uptake of PS antisense oligonucleotides (ASOs) within different cell types of the liver—a privileged organ for the discovery of oligonucleotide-based therapeutics.
SteinCA, SubasingheC, ShinozukaK and CohenJS. (1988). Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res, 16:3209–3221.
3.
LiangX-H, SunH, ShenW and CrookeST. (2015). Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res, 43:2927–2945.
4.
VickersTA and CrookeST. (2016). Development of a quantitative BRET affinity assay for nucleic acid-protein interactions. PLoS One, 11:e0161930.
5.
GearyRS, YuRZ and LevinAA. (2001). Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs, 2:562–573.
6.
BeltingerC, SaragoviHU, SmithRM, LeSauteurL, ShahN, DeDionisioL, ChristensenL, RaibleA, JarettL and GewirtzAM. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest, 95:1814–1823.
7.
SehgalA, VaishnawA and FitzgeraldK. (2013). Liver as a target for oligonucleotide therapeutics. J Hepatol, 59:1354–1359.
8.
KnolleP. (2007). Role and function of liver sinusoidal endothelial cells. In: Liver Immunology. GershwinME, VierlingJ and MannsM, eds. Humana Press, New York, pp. 25–39.
9.
ButlerM, SteckerK and BennettCF. (1997). Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest, 77:379–388.
10.
BijsterboschMK, ManoharanM, RumpET, De VruehRL, van VeghelR, TivelKL, BiessenEA, BennettCF, CookPD and van BerkelTJ. (1997). In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res, 25:3290–3296.
BraetF and WisseE. (2002). Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol, 1:1–17.
13.
BlouinA, BolenderRP and WeibelER. (1977). Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J Cell Biol, 72:441–455.
14.
WisseE, BraetF, LuoD, De ZangerR, JansD, CrabbeE and VermoesenA. (1996). Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol, 24:100–111.
15.
WisseE. (1970). An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastruct Res, 31:125–150.
16.
EnomotoK, NishikawaY, OmoriY, TokairinT, YoshidaM, OhiN, NishimuraT, YamamotoY and LiQ. (2004). Cell biology and pathology of liver sinusoidal endothelial cells. Med Electron Microsc, 37:208–215.
17.
PempeEH, XuY, GopalakrishnanS, LiuJ and HarrisEN. (2012). Probing structural selectivity of synthetic heparin binding to stabilin protein receptors. J Biol Chem, 287:20774–20783.
18.
MillerCM, DonnerAJ, BlankEE, EggerAW, KellarBM, OstergaardME, SethPP and HarrisEN. (2016). Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Nucleic Acids Res, 44:2782–2794.
19.
GoerdtS, WalshLJ, MurphyGF and PoberJS. (1991). Identification of a novel high molecular weight protein preferentially expressed by sinusoidal endothelial cells in normal human tissues. J Cell Biol, 113:1425–1437.
20.
IrjalaH, AlanenK, GrenmanR, HeikkilaP, JoensuuH and JalkanenS. (2003). Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res, 63:4671–4676.
21.
GoerdtS, BhardwajR and SorgC. (1993). Inducible expression of MS-1 high-molecular-weight protein by endothelial cells of continuous origin and by dendritic cells/macrophages in vivo and in vitro. Am J Pathol, 142:1409–1422.
22.
SzekaneczZ, HainesGK, LinTR, HarlowLA, GoerdtS, RayanG and KochAE. (1994). Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum, 37:221–231.
23.
KzhyshkowskaJ, GratchevA, MartensJH, PervushinaO, MamidiS, JohanssonS, SchledzewskiK, HansenB, HeX, et al. (2004). Stabilin-1 localizes to endosomes and the trans-Golgi network in human macrophages and interacts with GGA adaptors. J Leukoc Biol, 76:1151–1161.
24.
PrevoR, BanerjiS, NiJ and JacksonDG. (2004). Rapid plasma membrane-endosomal trafficking of the lymph node sinus and high endothelial venule scavenger receptor/homing receptor Stabilin-1 (FEEL-1/CLEVER-1). J Biol Chem, 279:52580–52592.
25.
HansenB, LongatiP, ElvevoldK, NedredalGI, SchledzewskiK, OlsenR, FalkowskiM, KzhyshkowskaJ, CarlssonF, et al. (2005). Stabilin-1 and Stabilin-2 are both directed into the early endocytic pathway in hepatic sinusoidal endothelium via interactions with clathrin/AP-2, independent of ligand binding. Exp Cell Res, 303:160–173.
26.
KzhyshkowskaJ, GratchevA, BrundiersH, MamidiS, KrusellL and GoerdtS. (2005). Phosphatidylinositide 3-kinase activity is required for Stabilin-1-mediated endosomal transport of acLDL. Immunobiology, 210:161–173.
27.
ZhangJ, GratchevA, RiabovV, MamidiS, SchmuttermaierC, KrusellL, KremmerE, WorkmanG, SageEH, et al. (2009). A novel GGA-binding site is required for intracellular sorting mediated by Stabilin-1. Mol Cell Biol, 29:6097–6105.
28.
KzhyshkowskaJ, GratchevA, SchmuttermaierC, BrundiersH, KrusellL, MamidiS, ZhangJ, WorkmanG, SageEH, et al. (2008). Alternatively activated macrophages regulate extracellular levels of the hormone placental lactogen via receptor-mediated uptake and transcytosis. J Immunol, 180:3028–3037.
29.
KzhyshkowskaJ, WorkmanG, Cardo-VilaM, ArapW, PasqualiniR, GratchevA, KrusellL, GoerdtS and SageEH. (2006). Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J Immunol, 176:5825–5832.
30.
ParkSY, JungMY, LeeSJ, KangKB, GratchevA, RiabovV, KzhyshkowskaJ and KimIS. (2009). Stabilin-1 mediates phosphatidylserine-dependent clearance of cell corpses in alternatively activated macrophages. J Cell Sci, 122:3365–3373.
31.
RashbaumIG. (2009). The sixth edition: self-directed physiatric education program (SDPEP) 2009. PM R, 1 (3 Suppl.):S1–S2.
32.
FalkowskiM, SchledzewskiK, HansenB and GoerdtS. (2003). Expression of Stabilin-2, a novel fasciclin-like hyaluronan receptor protein, in murine sinusoidal endothelia, avascular tissues, and at solid/liquid interfaces. Histochem Cell Biol, 120:361–369.
33.
QianH, JohanssonS, McCourtP, SmedsrodB and EkblomM. (2009). Stabilins are expressed in bone marrow sinusoidal endothelial cells and mediate scavenging and cell adhesive functions. Biochem Biophys Res Commun, 390:883–886.
34.
ZhouB, WeigelJA, SaxenaA and WeigelPH. (2002). Molecular cloning and functional expression of the rat 175-kDa hyaluronan receptor for endocytosis. Mol Biol Cell, 13:2853–2868.
35.
LewisSL, PatelPR, PaltaM, YooDS and SalamaJK. (2016). In reply to Fiorino and Cozzarini. Int J Radiat Oncol Biol Phys, 94:860–861.
36.
ZhouB, McGaryCT, WeigelJA, SaxenaA and WeigelPH. (2003). Purification and molecular identification of the human hyaluronan receptor for endocytosis. Glycobiology, 13:339–349.
37.
HarrisEN, KyossevaSV, WeigelJA and WeigelPH. (2007). Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J Biol Chem, 282:2785–2797.
38.
PandeyMS, HarrisEN, WeigelJA and WeigelPH. (2008). The cytoplasmic domain of the hyaluronan receptor for endocytosis (HARE) contains multiple endocytic motifs targeting coated pit-mediated internalization. J Biol Chem, 283:21453–21461.
39.
Yannariello-BrownJ, ZhouB and WeigelPH. (1997). Identification of a 175 kDa protein as the ligand-binding subunit of the rat liver sinusoidal endothelial cell hyaluronan receptor. Glycobiology, 7:15–21.
40.
HarrisEN and WeigelPH. (2008). The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates a, c, and d bind to overlapping sites distinct from the sites for heparin, acetylated low-density lipoprotein, dermatan sulfate, and CS-E. Glycobiology, 18:638–648.
41.
HarrisEN, BaggenstossBA and WeigelPH. (2009). Rat and human HARE/Stabilin-2 are clearance receptors for high- and low-molecular-weight heparins. Am J Physiol Gastrointest Liver Physiol, 296:G1191–G1199.
42.
LiR, OteizaA, SorensenKK, McCourtP, OlsenR, SmedsrodB and SvistounovD. (2011). Role of liver sinusoidal endothelial cells and stabilins in elimination of oxidized low-density lipoproteins. Am J Physiol Gastrointest Liver Physiol, 300:G71–G81.
43.
ParkSY, KimSY, JungMY, BaeDJ and KimIS. (2008). Epidermal growth factor-like domain repeat of Stabilin-2 recognizes phosphatidylserine during cell corpse clearance. Mol Cell Biol, 28:5288–5298.
44.
MillerCM and HarrisEN. (2016). Antisense oligonucleotides: treatment strategies and cellular internalization. RNA Dis, 3:e1393.
45.
HarrisEN, WeigelJA and WeigelPH. (2008). The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin. J Biol Chem, 283:17341–17350.
46.
MillerCM, WanWB, SethPP, HarrisEN (2018). Endosomal escape of ASOs internalized by Stabilin receptors is regulated by Rab5C and EEA1 during endosomal maturation. Nucl Acid Ther, 28:86–96.
47.
WangS, SunH, TanowitzM, LiangX-H and CrookeST. (2017). Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res, 45:5309–5322.
48.
SchwartzAL, RupD and LodishHF. (1980). Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte. J Biol Chem, 255:9033–9036.
49.
PricerWE and AshwellG. (1971). The binding of desialylated glycoproteins by plasma membranes of rat liver. J Biol Chem, 246:4825–4833.
50.
HudginRL, PricerWE, AshwellG, StockertRJ and MorellAG. (1974). The isolation and properties of a rabbit liver binding protein specific for asialoglycoproteins. J Biol Chem, 249:5536–5543.
51.
D'SouzaAA and DevarajanPV. (2015). Asialoglycoprotein receptor mediated hepatocyte targeting—strategies and applications. J Control Release, 203:126–139.
52.
ParkEI, MiY, UnverzagtC, GabiusH-J and BaenzigerJU. (2005). The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acidα2,6GalNac. Proc Natl Acad Sci U S A, 102:17125–17129.
53.
SteirerLM, ParkEI, TownsendRR and BaenzigerJU. (2009). The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid α2,6-galactose. J Biol Chem, 284:3777–3783.
54.
SpiessM. (1990). The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry, 29:10009–10018.
55.
Stockert RJ. (1995). The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev, 75:591–609.
56.
WallDA, WilsonG and HubbardAL. (1980). The galactose-specific recognition system of mammalian liver: the route of ligand internalization in rat hepatocytes. Cell, 21:79–93.
57.
WallDA and HubbardAL. (1981). Galactose-specific recognition system of mammalian liver: receptor distribution on the hepatocyte cell surface. J Cell Biol, 90:687–696.
58.
GeuzeHJ, SlotJW, GStrousJAM, LodishHF and SchwartzAL. (1983). Intracellular site of asialoglycoprotein receptor-ligand uncoupling: double-label immunoelectron microscopy during receptor-mediated endocytosis. Cell, 32:277–287.
59.
BraunJR, WillnowTE, IshibashiS, AshwellG and HerzJ. (1996). The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit. J Biol Chem, 271:21160–21166.
60.
GeffenI, WesselsHP, RothJ, ShiaMA and SpiessM. (1989). Endocytosis and recycling of subunit H1 of the asialoglycoprotein receptor is independent of oligomerization with H2. EMBO J, 8:2855–2861.
61.
BiderMD, CescatoR, JenoP and SpiessM. (1995). High-affinity ligand binding to subunit H1 of the asialoglycoprotein receptor in the absence of subunit H2. Eur J Biochem, 230:207–212.
62.
TozawaR-I, IshibashiS, OsugaJ-I, YamamotoK, YagyuH, OhashiK, TamuraY, YahagiN, IizukaY, et al. (2001). Asialoglycoprotein receptor deficiency in mice lacking the major receptor subunit: its obligate requirement for the stable expression of oligomeric receptor. J Biol Chem, 276:12624–12628.
63.
MeierM, BiderMD, MalashkevichVN, SpiessM and BurkhardP. (2000). Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Biol, 300:857–865.
64.
GeffenI, FuhrerC, LeitingerB, WeissM, HuggelK, GriffithsG and SpiessM. (1993). Related signals for endocytosis and basolateral sorting of the asialoglycoprotein receptor. J Biol Chem, 268:20772–20777.
65.
KatzirZ, NardiN, GeffenI, FuhrerC and HenisYI. (1994). Dynamic interactions of the asialoglycoprotein receptor subunits with coated pits. Enhanced interactions of H2 following association with H1. J Biol Chem, 269:21568–21575.
66.
OzakiK, LeeR, LeeY and KawasakiT. (1995). The differences in structural specificity for recognition and binding between asialoglycoprotein receptors of liver and macrophages. Glycoconj J, 12:268–274.
67.
LeeRT and LeeYC. (1997). Facile synthesis of a high-affinity ligand for mammalian hepatic lectin containing three terminal n-acetylgalactosamine residues. Bioconjug Chem, 8:762–765.
68.
LeeYC and LeeRT. (2008). Interactions of oligosaccharides and glycopeptides with hepatic carbohydrate receptors. In: Carbohydrates in Chemistry and Biology. ErnstB, HartGW and SinaýP, eds. Wiley-VCH Verlag GmbH, Weinheim, Germany, pp. 549–561.
69.
MammenM, ChoiS-K and WhitesidesGM. (1998). Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed, 37:2754–2794.
70.
PrakashTP, YuJ, MigawaMT, KinbergerGA, WanWB, OstergaardME, CartyRL, VasquezG, LowA, et al. (2016). Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J Med Chem, 59:2718–2733.
71.
MigawaMT, PrakashTP, VasquezG, WanWB, YuJ, KinbergerGA, OstergaardME, SwayzeEE and SethPP. (2016). A convenient synthesis of 5′-triantennary N-acetyl-galactosamine clusters based on nitromethanetrispropionic acid. Bioorg Med Chem Lett, 26:2194–2197.
72.
NairJK, WilloughbyJL, ChanA, CharisseK, AlamMR, WangQ, HoekstraM, KandasamyP, Kel'inAV, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust rnai-mediated gene silencing. J Am Chem Soc, 136:16958–16961.
73.
MatsudaS, KeiserK, NairJK, CharisseK, ManoharanRM, KretschmerP, PengCG, VKiA, KandasamyP, et al. (2015). SiRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem Biol, 10:1181–1187.
74.
RajeevKG, NairJK, JayaramanM, CharisseK, TanejaN, O'SheaJ, WilloughbyJL, YuciusK, NguyenT, et al. (2015). Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem, 16:903–908.
75.
OstergaardME, YuJ, KinbergerGA, WanWB, MigawaMT, VasquezG, SchmidtK, GausHJ, MurrayHM, et al. (2015). Efficient synthesis and biological evaluation of 5′-GalNac conjugated antisense oligonucleotides. Bioconjug Chem, 26:1451–1455.
76.
KinbergerGA, PrakashTP, YuJ, VasquezG, LowA, ChappellA, SchmidtK, MurrayHM, GausH, et al. (2016). Conjugation of mono and di-galnac sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes. Bioorg Med Chem Lett, 26:3690–3693.
77.
SchmidtK, PrakashTP, DonnerAJ, KinbergerGA, GausHJ, LowA, OstergaardME, BellM, SwayzeEE and SethPP. (2017). Characterizing the effect of GalNac and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor. Nucleic Acids Res, 45:2294–2306.
78.
TanowitzM, HettrickL, RevenkoA, KinbergerGA, PrakashTP and SethPP. (2017). Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res, 45:12388–12400.
79.
GrahamMJ, CrookeST, MonteithDK, CooperSR, LemonidisKM, SteckerKK, MartinMJ and CrookeRM. (1998). In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther, 286:447–458.
80.
DonnerAJ, WancewiczEV, MurrayHM, GreenleeS, PostN, BellM, LimaWF, SwayzeEE and SethPP. (2017). Co-administration of an excipient oligonucleotide helps delineate pathways of productive and nonproductive uptake of phosphorothioate antisense oligonucleotides in the liver. Nucleic Acid Ther, 27:209–220.
81.
ButlerM, CrookeRM, GrahamMJ, LemonidisKM, LougheedM, MurraySF, WitchellD, SteinbrecherU and BennettCF. (2000). Phosphorothioate oligodeoxynucleotides distribute similarly in class a scavenger receptor knockout and wild-type mice. J Pharmacol Exp Ther, 292:489–496.
82.
EzzatK, AokiY, KooT, McCloreyG, BennerL, Coenen-StassA, O'DonovanL, LehtoT, Garcia-GuerraA, et al. (2015). Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides. Nano Lett, 15:4364–4373.
83.
ShemeshCS, YuRZ, GausHJ, SethPP, SwayzeEE, BennettFC, GearyRS, HenrySP and WangY. (2016). Pharmacokinetic and pharmacodynamic investigations of ION-353382, a model antisense oligonucleotide: using alpha-2-macroglobulin and murinoglobulin double-knockout mice. Nucleic Acid Ther, 26:223–235.
84.
GuvakovaMA, YakubovLA, VlodavskyI, TonkinsonJL and SteinCA. (1995). Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem, 270:2620–2627.
85.
VineyNJ, van CapelleveenJC, GearyRS, XiaS, TamiJA, YuRZ, MarcovinaSM, HughesSG, GrahamMJ, et al. (2016). Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet, 388:2239–2253.
